{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:25:34Z","timestamp":1794583534100,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.seminoncol.2026.152559","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:06:39Z","timestamp":1789139199000},"page":"152559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study"],"prefix":"10.1016","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2835-6474","authenticated-orcid":false,"given":"Christina","family":"Blagojevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Juurlink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zipursky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.seminoncol.2026.152559_bib0001","doi-asserted-by":"crossref","first-page":"E506","DOI":"10.5489\/cuaj.8161","article-title":"2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: management of castration-resistant prostate cancer (CRPC)","volume":"16","author":"Saad","year":"2022","journal-title":"Can Urol Assoc J"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152559_bib0002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1016\/j.seminoncol.2026.152559_bib0003","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0004","series-title":"Abiraterone acetate tablets. Product monograph","year":"2021"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152559_bib0005","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152559_bib0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.113.000099","article-title":"Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care","volume":"6","author":"DeGorter","year":"2013","journal-title":"Circ Cardiovasc Genet"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152559_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13229","article-title":"Effect of enzalutamide on PK of P-gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters","volume":"15","author":"Poondru","year":"2022","journal-title":"Clin Transl Sci"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152559_bib0008","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152559_bib0009","first-page":"1129","article-title":"2021 CCS dyslipidemia guideline","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111478","article-title":"The evidence base of the 10 most prescribed drugs in England, France, and the United States: a scoping review","volume":"174","author":"Fournier","year":"2024","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152559_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arter Thromb Vasc Biol"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2025.107073","article-title":"Comparative uptake of statins by hepatic organic anion transporting polypeptides","volume":"209","author":"Kiander","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0013","doi-asserted-by":"crossref","unstructured":"N. Safitri, M.F Alaina, D.AE. Pitaloka, R. Abdulah A narrative review of statin-induced rhabdomyolysis: molecular mechanism, risk factors, and management. Drug Healthc Patient Saf. 2021;13: 211-219. doi:10.2147\/DHPS.S333738.","DOI":"10.2147\/DHPS.S333738"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.03.010","article-title":"Mechanisms of statin-associated skeletal muscle-associated symptoms","volume":"154","author":"Bouitbir","year":"2020","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152559_bib0015","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1A289","article-title":"FDA adverse event reports on statin-associated rhabdomyolysis","volume":"36","author":"Omar","year":"2002","journal-title":"Ann Pharmacother"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152559_bib0016","article-title":"Rhabdomyolysis and acute kidney injury induced by the association of rosuvastatin and abiraterone: a case report and review of the literature","volume":"27","author":"Ould-Nana","year":"2021","journal-title":"J Oncol Pharm Pr"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152559_bib0017","article-title":"Acute renal failure due to rhabdomyolysis in relation to abiraterone and rosuvastatin","volume":"43","author":"Cintra","year":"2023","journal-title":"Nefrologia"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152559_bib0018","doi-asserted-by":"crossref","DOI":"10.1038\/clpt.2009.79","article-title":"ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin","volume":"86","author":"Keskitalo","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152559_bib0019","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2557","article-title":"The Clinical Pharmacogenetics Implementation Consortium guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and statin-associated musculoskeletal symptoms","volume":"111","author":"Cooper-DeHoff","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2018.10.017","article-title":"Genetic variability and population diversity of the human SLCO (OATP) transporter family","volume":"139","author":"Zhang","year":"2019","journal-title":"Pharmacol Res"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152559_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.1604","article-title":"Inhibitors of organic anion-transporting polypeptides 1B1 and 1B3: clinical relevance and regulatory perspective","volume":"60","author":"McFeely","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"21","key":"10.1016\/j.seminoncol.2026.152559_bib0022","doi-asserted-by":"crossref","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152559_bib0023","doi-asserted-by":"crossref","DOI":"10.1007\/s00228-013-1554-0","article-title":"Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers","volume":"69","author":"Chen","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0024","series-title":"Prevymis\u00ae (letermovir) tablets, for oral use; PREVYMIS\u00ae (letermovir) injection, for intravenous use","year":"2023"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152559_bib0025","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0b013e318160a542","article-title":"Drug\/drug interaction between lopinavir\/ritonavir and rosuvastatin in healthy volunteers","volume":"47","author":"Kiser","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152559_bib0026","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.106.014407","article-title":"The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3","volume":"35","author":"Seithel","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152559_bib0027","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-21-0023","article-title":"Regulation of OATP1B1 function by tyrosine kinase-mediated phosphorylation","volume":"27","author":"Hayden","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0028","series-title":"Epclusa\u00ae (sofosbuvir and velpatasvir) tablets, for oral use","year":"2017"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152559_bib0029","doi-asserted-by":"crossref","DOI":"10.1007\/s40262-023-01268-w","article-title":"Clinical pharmacokinetics and pharmacodynamics of the next generation androgen receptor inhibitor darolutamide","volume":"62","author":"Podgor\u0161ek","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152559_bib0030","doi-asserted-by":"crossref","DOI":"10.1007\/s40264-024-01415-7","article-title":"Enzalutamide: understanding and managing drug interactions to improve patient safety and drug efficacy","volume":"47","author":"Lennep","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0031","series-title":"ERLEADA (apalutamide) tablets, for oral use: prescribing information","year":"2026"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0032","series-title":"Nilutamide tablets, for oral use: prescribing information","year":"2026"},{"key":"10.1016\/j.seminoncol.2026.152559_bib0033","series-title":"Bicalutamide tablets, for oral use: prescribing information","year":"2026"},{"issue":"177","key":"10.1016\/j.seminoncol.2026.152559_bib0034","article-title":"Prescription cholesterol-lowering medication use in adults aged 40 and over: united States, 2003-2012","author":"Gu","year":"2014","journal-title":"NCHS Data Br"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:31:39Z","timestamp":1794580299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0093775426001041"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152559","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rhabdomyolysis resulting from the interaction of rosuvastatin and abiraterone: A case study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152559","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152559"}}